Strikingly, decreasing the endogenous C/EBPα-p30/C/EBPα ratio had a potential supplementary therapeutic effect through its LLPS, providing a novel therapeutic approach for AML. This evidence concerns the gene CEBPA and acute myeloid leukemia.